Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Valdecoxib

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pfizer's Bextra settlement tagged at $486M
    Pfizer's Bextra settlement tagged at $486M

    03 Aug 2016

    // Eric Palmer FIERCE PHARMA

    http://www.fiercepharma.com/pharma/pfizer-s-bextra-settlement-tagged-at-486m

    Eric Palmer FIERCE PHARMA
    03 Aug 2016
    Share Share
    Pfizer (PFE) to Fork Over $486 Million to Settle Lawsuit Over Celebrex, Bextra
    Pfizer (PFE) to Fork Over $486 Million to Settle Lawsuit Over Celebrex, Bextra

    03 Aug 2016

    // BIOSPACE

    http://www.biospace.com/News/pfizer-to-fork-over-486-million-to-settle-lawsuit/428174/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews

    BIOSPACE
    03 Aug 2016
    Share Share
    Pfizer agrees to settle shareholder class action on Celebrex and Bextra
    Pfizer agrees to settle shareholder class action on Celebrex and Bextra

    01 Aug 2016

    // Eric Palmer FIERCE PHARMA

    http://www.fiercepharma.com/pharma/pfizer-agrees-to-settle-shareholder-class-action-celebrex-and-bextra

    Eric Palmer FIERCE PHARMA
    01 Aug 2016
    Share Share
    Pfizer must face revived Celebrex, Bextra safety lawsuit
    Pfizer must face revived Celebrex, Bextra safety lawsuit

    13 Apr 2016

    // Jonathan Stempel REUTERS

    http://www.reuters.com/article/us-pfizer-lawsuit-idUSKCN0X91SF

    Jonathan Stempel REUTERS
    13 Apr 2016
    Share Share
    Pfizer to Pay $400 Million to Avert Investor Class Action Trial
    Pfizer to Pay $400 Million to Avert Investor Class Action Trial

    28 Jan 2015

    //  Nate Raymond REUTERS

    http://www.reuters.com/article/2015/01/27/pfizer-classaction-idUSL1N0V61YR20150127

     Nate Raymond REUTERS
    28 Jan 2015
    Share Share